Lilly’s New Anti-Amyloid Play Hinges On Tau Bet
Redesigned Phase III Trial May Confirm Phase II Donanemab Results
TRAILBLAZER-ALZ met the primary, but not most secondary endpoints. Lilly said efficacy of its amyloid-clearing agent depends on tau levels at baseline and reductions in some parts of the brain.
You may also be interested in...
Experts say there should be enough Alzheimer’s patients willing to enroll in Biogen/Eisai’s US FDA-required Phase IV trial and other companies’ late-stage studies even with Aduhelm broadly available.
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.
With disappointing revenues during Q1 due to the pandemic impact on sales and price pressure on Taltz, the pharma gave a long-term, pipeline-focused growth narrative. Alzheimer's filing plans pushed back.